Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
Biomerica (NASDAQ: BMRA) announces direct-to-consumer availability of its inFoods® IBS test through infoodsibs.com. The test, which requires only a finger-prick blood sample, helps identify foods triggering IBS symptoms like bloating and gastrointestinal pain. A licensed physician remotely authorizes the test, eliminating the need for office visits.
The technology's effectiveness was validated in a double-blinded, placebo-controlled multicenter clinical study at institutions including Mayo Clinic and Beth Israel Deaconess Medical Center, showing significant improvement in symptoms without medication side effects. The solution targets a considerable market, as IBS affects 1 in 20 Americans and contributes to $10 billion in annual direct medical costs.
Biomerica (NASDAQ: BMRA) annuncia la disponibilità diretta al consumatore del suo test inFoods® IBS attraverso infoodsibs.com. Il test, che richiede solo un campione di sangue prelevato da un dito, aiuta a identificare gli alimenti che scatenano sintomi dell'IBS come gonfiore e dolore gastrointestinali. Un medico autorizzato esegue il test a distanza, eliminando la necessità di visite in ambulatorio.
L'efficacia della tecnologia è stata convalidata in uno studio clinico multicentrico, in doppio cieco e controllato con placebo, presso istituzioni tra cui la Mayo Clinic e il Beth Israel Deaconess Medical Center, dimostrando un miglioramento significativo dei sintomi senza effetti collaterali da farmaci. La soluzione mira a un mercato considerevole, poiché l'IBS colpisce 1 persona su 20 negli Stati Uniti e contribuisce a 10 miliardi di dollari in costi medici diretti annuali.
Biomerica (NASDAQ: BMRA) anuncia la disponibilidad directa al consumidor de su prueba inFoods® IBS a través de infoodsibs.com. La prueba, que solo requiere una muestra de sangre de una punción en el dedo, ayuda a identificar los alimentos que desencadenan síntomas del SII, como hinchazón y dolor gastrointestinal. Un médico autorizado aprueba la prueba de forma remota, eliminando la necesidad de visitas de oficina.
La efectividad de la tecnología fue validada en un estudio clínico multicéntrico, aleatorizado y controlado por placebo en instituciones como Mayo Clinic y Beth Israel Deaconess Medical Center, mostrando una mejora significativa en los síntomas sin efectos secundarios por medicamentos. La solución apunta a un mercado considerable, ya que el SII afecta a 1 de cada 20 estadounidenses y contribuye con $10 mil millones en costos médicos directos anuales.
Biomerica (NASDAQ: BMRA)는 infoodsibs.com을 통해 소비자에게 직접 inFoods® IBS 테스트를 제공한다고 발표했습니다. 이 테스트는 손가락에서 채취한 혈액 샘플만을 필요로 하며, 복부 팽만감과 위장 통증과 같은 IBS 증상을 유발하는 음식을 식별하는 데 도움이 됩니다. 면허를 가진 의사가 원격으로 테스트를 승인하여 병원 방문의 필요성을 없앱니다.
이 기술의 효과는 Mayo Clinic 및 Beth Israel Deaconess Medical Center를 포함한 기관에서 실시된 이중 맹검, 위약 대조 다기관 Clinical Study에서 검증되어 약물 부작용 없이 증상이 유의미하게 개선되었음을 보여주었습니다. 이 솔루션은 IBS가 20명 중 1명에게 영향을 미치고, 매년 100억 달러의 직접 의료 비용에 기여하는 상당한 시장을 겨냥하고 있습니다.
Biomerica (NASDAQ: BMRA) annonce la disponibilité directe au consommateur de son test inFoods® IBS via infoodsibs.com. Le test, qui ne nécessite qu'un échantillon de sang prélevé au doigt, aide à identifier les aliments déclenchant des symptômes de l'IBS tels que des ballonnements et des douleurs gastrointestinales. Un médecin agréé autorise le test à distance, éliminant ainsi la nécessité de visites au cabinet.
L'efficacité de la technologie a été validée dans une étude clinique multicentrique en double aveugle contrôlée par placebo dans des établissements tels que la Mayo Clinic et le Beth Israel Deaconess Medical Center, montrant une amélioration significative des symptômes sans effets secondaires liés aux médicaments. La solution cible un marché considérable, car l'IBS touche 1 Américain sur 20 et contribue à 10 milliards de dollars de coûts médicaux directs annuels.
Biomerica (NASDAQ: BMRA) gibt die direkte Verfügbarkeit seines inFoods® IBS-Tests über infoodsibs.com bekannt. Der Test, der nur eine Blutprobe aus einem Fingerstich erfordert, hilft dabei, Lebensmittel zu identifizieren, die IBS-Symptome wie Blähungen und gastrointestinale Schmerzen auslösen. Ein lizenzierter Arzt genehmigt den Test aus der Ferne, was den Bedarf an Arztbesuchen eliminiert.
Die Wirksamkeit der Technologie wurde in einer doppelblinden, placebokontrollierten multizentrischen klinischen Studie an Institutionen wie der Mayo Clinic und dem Beth Israel Deaconess Medical Center validiert, die eine signifikante Verbesserung der Symptome ohne Nebenwirkungen von Medikamenten zeigte. Die Lösung zielt auf einen erheblichen Markt ab, da IBS 1 von 20 Amerikanern betrifft und jährlich 10 Milliarden Dollar an direkten medizinischen Kosten verursacht.
- Direct-to-consumer availability expands market access and revenue potential
- Clinical validation from prestigious institutions strengthens product credibility
- Addresses $10 billion annual direct medical cost market
- Remote physician authorization streamlines customer acquisition
- None.
Insights
The direct-to-consumer launch of inFoods® IBS test represents a significant market opportunity for Biomerica. The test's validation through a multi-center clinical trial at prestigious institutions adds substantial credibility. With
The test's competitive advantages include:
- Physician-authorized remote ordering system eliminating office visit barriers
- Non-invasive finger-prick blood sampling
- Personalized results targeting specific trigger foods
- Medication-free approach backed by clinical evidence
The direct-to-consumer strategy positions Biomerica to capture value in the growing personalized medicine market. Key market dynamics support this launch:
- Rising consumer demand for at-home diagnostic testing post-pandemic
- Increasing preference for natural treatment approaches over medications
- Growing awareness of food sensitivity impacts on health
- Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s office
- With a simple, at-home finger-prick blood sample, patients can receive a personalized test result identifying potential IBS trigger foods
- The inFoods® IBS test empowers patients with actionable results to reduce bloating and gastrointestinal pain
IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods® IBS test directly from infoodsibs.com and consequently collect a sample in the comfort of their home. As part of this ordering process, a licensed physician remotely authorizes the test, ensuring professional medical oversight, without the need for visiting a doctor’s office.
A New Era in IBS Treatment with At-Home Convenience.
The InFoods IBS test provides a breakthrough tool for individuals with Irritable Bowel Syndrome (IBS) who seek to manage symptoms such as bloating and gastrointestinal pain. The inFoods® IBS test offers a personalized and non-invasive solution, helping patients to manage their condition naturally by identifying foods that may trigger their symptoms. Now, patients can access the inFoods IBS test from the comfort of their home with physician oversight, offering a more convenient pathway to health management helping IBS patients to regain control of their life.
The inFoods® IBS test is a groundbreaking advancement in the personalized treatment of IBS. Unlike IBS treatments that rely on medications to reduce symptoms, inFoods® IBS identifies specific foods that may trigger the patient´s symptoms allowing for tailored dietary changes that can reduce both bloating and gastrointestinal pain, encouraging patients to manage their condition naturally by avoiding the problematic foods identified by the inFoods IBS test. The test uses a patented technology to detect personal food sensitivities, helping patients achieve significant symptom relief by removing those trigger foods from their diet.
A recent double-blinded, placebo-controlled, multicenter clinical study—conducted at prestigious institutions including Mayo Clinic, Beth Israel Deaconess Medical Center (a Harvard Medical School teaching hospital), the University of Michigan, and Houston Methodist Hospital—demonstrated that the inFoods® IBS test significantly improved key IBS symptoms, such as Abdominal Pain Intensity (API) and bloating. Patients in the treatment group experienced significant symptom improvements but without the side effects commonly associated with drug therapies.
IBS: A Widespread Condition with High Economic Impact.
Irritable Bowel Syndrome affects 1 in 20 Americans, according to the American College of Gastroenterology, contributing to an estimated
Biomerica’s InFoods® IBS platform offers new hope for millions of IBS sufferers by providing a tailored approach to treatment that addresses the root causes of their symptoms. To learn more or to seamlessly order the test with physician oversight, visit inFoodsIBS.com.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
About inFoods®
The inFoods IBS test is designed to assess a patient’s above normal immunoreactivity to specific foods utilizing a simple finger-stick blood sample. Instead of difficult to manage broad dietary restrictions, physicians can now use the inFoods IBS information to make targeted, patient-specific recommendations about trigger foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The inFoods IBS test and clinical outcomes were studied at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The clinical results for improvement in the Abdominal Pain Intensity (API) responder endpoint of >
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s current and future sales, efficacy of the Company’s products and tests, , uniqueness of the Company’s products, accuracy of the Company’s tests and products, future use of the Company's products by physicians to treat their patients. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company’s inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversite, and the Company’s ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani
949-645-2111
investors@biomerica.com
Source: Biomerica, Inc.
FAQ
What is the new direct-to-consumer offering from Biomerica (BMRA)?
How does Biomerica's (BMRA) inFoods IBS test work?
What clinical validation supports Biomerica's (BMRA) inFoods IBS test?
What is the market size for Biomerica's (BMRA) IBS solution?
